Search using our robust engine. Get the recommendations you need to get ahead.
Browse through our expansive list of legal practice areas.
Work where you are or where you’d like to be. Find where you’ll work with LawCrossing.
Use our marketplace to feature your opportunity
Start your search today
Set up your account and manage your company profile on LawCrossing
Look through and compare company profiles
Learn from legal expert, Harrison Barnes
Discovery salaries and scope your next job
Don’t just take it from us
How to Attract Success
Why You Should Never Miss a Company Holiday Party or Invitation to Your Boss’s Home
Our first approved product, ARCALYST® (rilonacept), an anti-inflammatory agent, has been available to patients in the U.S. since 2008. In late 2011, we launched EYLEA® (aflibercept) Injection, also known in the scientific literature as VEGF Trap-Eye and Intravitreal Aflibercept Injection, and received approval from the FDA for a second indication in September 2012. In August 2012, Regeneron and Sanofi, obtained FDA approval for ZALTRAP® (ziv-aflibercept) Injection for Intravenous Infusion.